Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

(2018) Hillel P. Cohen et al.   DRUGS

Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars

(2017) András Inotai et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis

(2017) Yuga Komaki et al.   JOURNAL OF AUTOIMMUNITY

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

(2017) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

(2017) Martin Schiestl et al.   Drug Design Development and Therapy

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician

(2017) Robert Moots et al.   Current Rheumatology Reports

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

(2017) Robert J. Moots et al.   PLoS One

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

(2016) Alison Smith et al.   Journal of Immunology Research

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis

(2015) Rajendrakumar H. Jani et al.   International Journal of Rheumatic Diseases

Biologics and biosimilars

(2015) Palak K. Patel et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

(2013) Stef P. Menting et al.   JAMA Dermatology

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY